Literature DB >> 1385954

Lipoprotein(a) in subjects with familial defective apolipoprotein B100.

Y F Perombelon1, J J Gallagher, N B Myant, A K Soutar, B L Knight.   

Abstract

The plasma lipoprotein(a) (Lp(a)) concentration and apolipoprotein(a) (apo(a)) phenotype were determined in the members of two families affected with familial defective apo B100 (FDB), resulting from the Arg3500----Gln mutation in apo B that disrupts binding to LDL receptors. Eleven different phenotypic species of apo A were identified, five of which were present in both families. Although there was a general increase in Lp(a) concentration as the size of the predominant apo(a) component decreased, there was considerable variability and in three clear instances the concentration of an inherited phenotypic species was atypically low. In five cases where a direct comparison could be made, the plasma Lp(a) concentration was significantly higher in heterozygous FDB subjects than in their non-FDB siblings or close relatives with the same phenotype. However, in vitro competition studies using purified Lp(a) that had been reduced with dithiothreitol to remove the apo(a) component, indicated that the Lp(a) from FDB heterozygotes contained a smaller proportion of defective particles than their LDL. Lp(a) particles containing normal and binding-defective apo B were present at approximately the same concentration, suggesting that the increase in Lp(a) concentration observed in FDB subjects could not be explained by the inability of the particles containing the defective apo B100 to be cleared through LDL-receptor mediated processes.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385954     DOI: 10.1016/0021-9150(92)90279-p

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  6 in total

1.  Sib-pair analysis detects elevated Lp(a) levels and large variation of Lp(a) concentration in subjects with familial defective ApoB.

Authors:  Y Y van der Hoek; A Lingenhel; H G Kraft; J C Defesche; J J Kastelein; G Utermann
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

2.  Variation in lipoprotein(a) concentration associated with different apolipoprotein(a) alleles.

Authors:  Y F Perombelon; A K Soutar; B L Knight
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

3.  Lipoprotein (a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia.

Authors:  G F Watts; E M Kearney; N A Taub; B M Slavin
Journal:  J Clin Pathol       Date:  1993-03       Impact factor: 3.411

4.  Apolipoprotein E phenotype and lipoprotein(a) in familial hypercholesterolaemia: implication for lipoprotein(a) metabolism.

Authors:  G Lindahl; F Mailly; S Humphries; M Seed
Journal:  Clin Investig       Date:  1994-08

5.  The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma.

Authors:  E Steyrer; S Durovic; S Frank; W Giessauf; A Burger; H Dieplinger; R Zechner; G M Kostner
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

6.  The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans.

Authors:  D J Rader; W A Mann; W Cain; H G Kraft; D Usher; L A Zech; J M Hoeg; J Davignon; P Lupien; M Grossman
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.